Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors
In the last decade, immunotherapy has completely changed the therapeutic armamentarium of patients with genitourinary tumors. In particular, the approval of anti-Programmed-death-1 (PD-1) agents in patients with renal cell carcinoma (RCC) and bladder cancer (BC) has increased their life expectancy, with a generally tolerated toxicity profile. On the contrary, patients with prostate cancer (PCa) seem to scarcely benefit from this strategy.
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Francesco Carrozza, Matteo Santoni, Francesco Piva, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, Rodolfo Montironi, Nicola Battelli, Stefano Tamberi Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Hematology | Immunotherapy | Kidney Cancer | Prostate Cancer | Renal Cell Carcinoma | Toxicology